List of Excipients in Branded Drug RIVAROXABAN

Generic Drugs Containing RIVAROXABAN

Company	Ingredient	NDC	Excipient
Indoco Remedies Limited	rivaroxaban	14445-147	CELLULOSE, MICROCRYSTALLINE
Indoco Remedies Limited	rivaroxaban	14445-147	CROSCARMELLOSE SODIUM
Indoco Remedies Limited	rivaroxaban	14445-147	FERRIC OXIDE YELLOW
Indoco Remedies Limited	rivaroxaban	14445-147	HYPROMELLOSES

What are the Most Frequently-Used Excipients in RIVAROXABAN?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
3	ANHYDROUS LACTOSE
1	CARBOXYMETHYLCELLULOSE SODIUM
14	CELLULOSE, MICROCRYSTALLINE

Rivaroxaban Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Rivaroxaban is a low-solubility oral anticoagulant with established generic competition and continuing opportunities in pediatric delivery, oral suspensions, modified-release platforms, fixed-dose combinations, and excipient-enabled bioavailability improvement. The strongest commercial strategies focus on formulation performance, manufacturing robustness, patient usability, and geographic regulatory efficiency rather than simple replication of Xarelto tablets.

What is the formulation and excipient profile of rivaroxaban?

Rivaroxaban is a selective direct factor Xa inhibitor marketed by Bayer and Janssen as Xarelto. It is administered in multiple strengths and dosage forms, including immediate-release tablets and an oral suspension for pediatric and selected adult use.

What excipients are used in Xarelto tablets?

Xarelto tablet formulations use conventional pharmaceutical excipients. The inactive ingredient profile varies by strength and product presentation, but commonly includes:

Excipient category	Representative excipients	Primary function
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass and compressibility
Binder or film former	Hypromellose	Granulation, coating and mechanical strength
Disintegrant	Croscarmellose sodium	Tablet breakup and dispersion
Surfactant or wetting agent	Sodium lauryl sulfate	Wetting and dissolution support
Lubricant	Magnesium stearate	Ejection and manufacturing control
Coating agent	Hypromellose, polyethylene glycol	Film formation and appearance
Opacifier	Titanium dioxide	Opacity and light protection
Colorants	Ferric oxide pigments	Strength identification

The 2.5 mg, 10 mg, 15 mg and 20 mg tablets require different risk assessments because rivaroxaban loading increases as the dose increases while the excipient system remains relatively similar. Low-dose tablets have a particularly high active-to-excipient surface-area ratio, creating greater sensitivity to blend uniformity, segregation and content uniformity.

Why does rivaroxaban need an excipient strategy?

Rivaroxaban has low aqueous solubility and is classified as a low-solubility compound in common biopharmaceutic assessments. Particle size, wetting, solid-state properties, granulation and tablet disintegration can affect dissolution performance.

The 15 mg and 20 mg products are taken with food under the approved labeling because food improves absorption at those doses. The 2.5 mg and 10 mg products can be administered with or without food, subject to indication-specific instructions.[1] This creates an important formulation boundary: a generic or differentiated product that seeks broader administration conditions must demonstrate clinical and regulatory equivalence rather than relying only on excipient substitution.

What excipient technologies can improve rivaroxaban performance?

The most commercially relevant technologies are those that improve dissolution, reduce dose variability, simplify administration or support pediatric dosing.

Particle-size engineering

Micronization and controlled particle-size distributions can increase surface area and accelerate dissolution. The main development risks are:

• Electrostatic charging during milling and blending.
• Agglomeration and poor powder flow.
• Content-uniformity failures at the 2.5 mg strength.
• Changes in dissolution after scale-up.
• Increased sensitivity to humidity and mechanical energy.

Particle-size claims may have limited standalone patent strength if the range is routine or overlaps prior art. Stronger protection generally requires a defined particle-size distribution tied to a measurable dissolution, exposure or stability result.

Wetting-agent systems

Sodium lauryl sulfate and other surfactants can improve wetting of hydrophobic rivaroxaban particles. Alternative candidates include poloxamers, polysorbates and certain sodium sulfosuccinate systems.

A surfactant strategy must control:

• Peroxide and aldehyde impurities.
• Interaction with coating polymers.
• Taste and mucosal tolerability in liquid products.
• Foam generation during suspension manufacture.
• Stability in aqueous multidose packaging.

Surfactant substitution can create a low-cost generic opportunity, but it may also alter dissolution enough to trigger additional bioequivalence risk.

Amorphous solid dispersions

Polymers such as hypromellose acetate succinate, copovidone, polyvinylpyrrolidone and hydroxypropyl cellulose can maintain rivaroxaban in a higher-energy amorphous state and increase apparent solubility.

The commercial case is strongest where the formulation can deliver one or more of the following:

• Faster dissolution in biorelevant media.
• Lower food dependence.
• Reduced tablet size.
• Improved exposure at pediatric doses.
• A stable product with a demonstrated crystallization barrier.

The principal development risks are recrystallization, moisture uptake, residual solvent, thermal stress and physical instability during long-term storage. A solid-dispersion product may also move farther from a conventional generic pathway and require a more complex comparative clinical package.

Lipid-based and self-emulsifying systems

Lipid excipients, medium-chain triglycerides, mixed glycerides and self-emulsifying delivery systems can address low solubility. These platforms are more suitable for softgels, oral liquids or specialized pediatric products than for standard compressed tablets.

A lipid system must be evaluated for:

• Dose uniformity during filling.
• Capsule compatibility.
• Oxidative stability.
• Food-effect behavior.
• Drug precipitation after dilution in gastrointestinal fluid.
• Packaging interaction.

This approach may provide a stronger product differentiation position but usually carries higher manufacturing and regulatory complexity.

Cyclodextrin and pH-modifying systems

Cyclodextrins can improve apparent solubility in liquid or rapidly dispersing products. Acidifying or buffering agents may also improve dissolution in selected dosage forms.

The main constraints are excipient load, osmolality, gastrointestinal tolerability, cost and the need to prove that complexation does not materially change exposure. These systems are most commercially relevant for oral suspensions, sachets and hospital-use presentations.

What excipients are relevant to rivaroxaban oral suspension?

Xarelto oral suspension provides a regulatory benchmark for liquid delivery. The product uses a dry granule system that is reconstituted before administration and contains excipients such as hypromellose, mannitol, polysorbate 20, sodium benzoate, sucralose and citric acid, with product-specific inactive-ingredient details set out in the FDA labeling.[2]

A competitive suspension strategy should prioritize:

1. A 1 mg/mL or otherwise clinically convenient concentration.
2. Low sedimentation and rapid redispersibility.
3. Accurate dosing through an oral syringe.
4. Acceptable taste masking.
5. Microbiological control after reconstitution.
6. Stable potency throughout the labeled in-use period.
7. Compatibility with common pediatric feeding practices.

What taste-masking technologies are commercially attractive?

Rivaroxaban has a bitter active ingredient profile. Potential approaches include:

• Polymer coating of drug particles.
• Ion-exchange resin complexes.
• Lipid encapsulation.
• Cyclodextrin complexation.
• High-intensity sweeteners.
• Flavor systems combined with viscosity control.

Taste masking can create meaningful differentiation for pediatric products. The formulation must still support rapid release after swallowing and avoid excessive particle size or insoluble coating residue.

What are the principal suspension failure modes?

The highest-risk failure modes are sedimentation, caking, nonuniform withdrawal, preservative loss, microbial growth and dosing-device incompatibility. A formulation that passes release testing but produces variable doses after repeated household use has limited commercial value.

What formulation patents protect rivaroxaban products?

Rivaroxaban has been protected by compound, formulation, dosage-regimen and method-of-use patent families. The foundational U.S. compound patent commonly associated with Xarelto is U.S. Patent No. 7,157,456. Later patent activity has included formulation, dosing and clinical-use claims.

How strong is the rivaroxaban patent estate?

The estate is weaker for conventional immediate-release tablets than for differentiated delivery systems. A standard tablet containing known excipients is generally exposed to:

• Expired or expiring compound protection.
• Generic substitution.
• Abbreviated new drug application pathways.
• Prior-art challenges against routine excipient combinations.
• Design-around opportunities involving particle size, granulation and coating.

Patent strength is higher where claims require a specific combination of:

• Rivaroxaban solid-state form.
• Particle-size distribution.
• Polymer or surfactant ratio.
• Dissolution profile.
• Food-effect limitation.
• Stability performance.
• Pediatric concentration and dosing device.
• Manufacturing sequence or process parameter.

A formulation patent should connect the composition to a measurable technical result. Broad claims covering only "rivaroxaban plus a pharmaceutically acceptable excipient" are vulnerable to enablement, written-description and obviousness challenges.

What manufacturing and intellectual-property barriers remain?

Potential barriers include:

• Controlled crystallization or amorphous-state production.
• High-shear granulation and drying parameters.
• Content uniformity at low strengths.
• Specialized coating equipment.
• Suspension reconstitution and filling controls.
• Taste-masked particles.
• Device compatibility and dose-delivery accuracy.

Manufacturing know-how may provide practical protection even when patent protection is limited. However, trade-secret protection is less effective for a tablet that can be chemically and physically characterized after market entry.

When does rivaroxaban lose exclusivity?

U.S. commercial exclusivity depends on the interaction between patent expiration, pediatric exclusivity, litigation settlements, regulatory exclusivity and any enforceable formulation or method-of-use patents.

Protection type	Strategic relevance
Compound patent	Controls the earliest broad generic entry opportunity
Formulation patent	May delay or narrow specific dosage-form competition
Method-of-use patent	Can affect labeling, carve-outs and induced-infringement risk
Pediatric exclusivity	Can extend listed patent or exclusivity protection by six months
Regulatory exclusivity	May affect approval timing for specific presentations
Settlement agreement	Can establish an agreed generic launch date before final patent expiry

The original rivaroxaban compound protection has been publicly associated with U.S. Patent No. 7,157,456, whose listed term was subject to statutory adjustments and pediatric exclusivity. Product-specific entry timing must be confirmed against the current FDA Orange Book, patent-term records and any settlement provisions.[3]

What is the Orange Book status of Xarelto?

The FDA Orange Book is the controlling source for listed patents, expiration dates, pediatric extensions, exclusivity codes and approved therapeutic equivalents. Xarelto listings have included multiple strengths and dosage forms, and the listed patent profile can differ by presentation.

An applicant assessing rivaroxaban should review:

• Each Xarelto NDA presentation.
• Listed patent numbers and expiration dates.
• Pediatric exclusivity notation.
• Patent certifications in the ANDA.
• Any delisting or expiration updates.
• Whether a proposed product relies on the same indication and dosage form.

Orange Book review is essential because a patent may be relevant to one strength or use but not another.[4]

Which companies are challenging Xarelto?

Generic pharmaceutical companies have pursued or evaluated rivaroxaban through ANDA filings and patent challenges. Publicly reported Xarelto patent litigation has involved major generic manufacturers, including companies such as Teva and related generic competitors, depending on the patent and litigation period.

The relevant competitive question is no longer whether generic rivaroxaban is technically feasible. It is whether a company can obtain an economically attractive launch position with acceptable litigation exposure, manufacturing cost and supply reliability.

A Paragraph IV strategy can provide earlier market entry but creates exposure to:

• Hatch-Waxman litigation.
• Injunction risk.
• Damages or settlement restrictions.
• Launch-at-risk liability.
• Regulatory delay if patent certification issues remain unresolved.

What generic entry risks exist for rivaroxaban?

Standard tablet risk

The standard tablet market is likely to face price compression once multiple therapeutically equivalent products enter. The 10 mg and 20 mg strengths may attract the largest volume because of broad use across venous thromboembolism and atrial fibrillation indications.

Pediatric suspension risk

The pediatric suspension has greater formulation and device complexity. Competition may be slower because applicants must address reconstitution, in-use stability, taste, dosing accuracy and age-specific use.

Method-of-use risk

Rivaroxaban has multiple indications, including stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of venous thromboembolism, and selected cardiovascular risk-reduction uses. A generic applicant may need indication-specific labeling analysis and appropriate carve-outs to avoid infringing protected uses.

Biosimilar risk

Biosimilar competition is not relevant to rivaroxaban. Rivaroxaban is a chemically synthesized small molecule regulated through the generic drug pathway, principally under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The competitive threat comes from generic manufacturers, not biosimilar developers.

What are the commercial opportunities for excipient suppliers?

Excipient suppliers can target five segments.

Functional excipients for dissolution

Suppliers can offer low-peroxide surfactants, polymeric solubilizers, copovidone systems and engineered cellulose products supported by rivaroxaban dissolution data.

Pediatric suspension platforms

Ready-to-use or reconstituted suspension platforms can combine suspending agents, sweeteners, preservatives, buffers and flavor systems. The value proposition is a validated platform with reduced development time and reproducible redispersion.

Taste-masking systems

Coated particles, resin complexes and lipid-based barriers can support pediatric and geriatric products. Suppliers with scalable coating and analytical characterization capabilities have the strongest position.

Direct-compression systems

A co-processed excipient system that improves flow, blend uniformity and tablet hardness could reduce manufacturing cost, particularly for the 2.5 mg strength.

Global regulatory packages

Excipient suppliers can differentiate through documentation covering:

• Compendial compliance.
• Elemental impurities.
• Nitrosamine risk.
• Peroxide and aldehyde controls.
• Residual solvents.
• TSE/BSE status.
• Genetically modified organism status.
• Regional food and pharmaceutical approvals.
• Change-control history.

What licensing deals could support rivaroxaban products?

Licensing opportunities are most credible in three areas:

1. A differentiated pediatric suspension or taste-masked product.
2. A bioavailability-enhanced formulation with reduced food dependence.
3. A co-development arrangement combining an excipient platform with an established generic manufacturer.

A simple excipient supply agreement is more likely than a molecule-specific royalty license for conventional tablets. A platform owner can improve negotiating leverage by providing formulation know-how, scale-up data, regulatory support and freedom-to-operate analysis.

Potential partners include generic pharmaceutical companies, pediatric specialty manufacturers, oral-liquid CDMOs, excipient developers and regional licensees in markets where Xarelto access remains limited.

How does rivaroxaban compare with competing anticoagulants?

Product	Active ingredient	Dosage-form opportunity	Excipient opportunity	Competitive position
Xarelto	Rivaroxaban	Tablets and oral suspension	Pediatric delivery, dissolution and taste masking	Strong originator recognition
Eliquis	Apixaban	Primarily tablets	Low-dose content uniformity and alternative delivery	Major direct oral anticoagulant competitor
Pradaxa	Dabigatran etexilate	Capsules and pellets	Moisture protection and capsule stability	Distinct formulation constraints
Savaysa	Edoxaban	Tablets	Standard generic tablet strategy	Smaller commercial base
Warfarin	Warfarin sodium	Tablets and liquids	Dose flexibility and compounding	Low-cost, monitoring-intensive alternative

Rivaroxaban has a broader formulation opportunity than products limited to a single tablet presentation. Its pediatric suspension and multiple dose strengths create more avenues for excipient-enabled differentiation.

What is the revenue exposure from generic rivaroxaban?

Xarelto has been one of the largest pharmaceutical products in the anticoagulant market, with global sales measured in the multibillion-dollar range in peak years. Generic entry threatens branded revenue through rapid price erosion, formulary substitution and tender pressure.

Revenue exposure differs by market:

• The United States is highly sensitive to patent and settlement timing.
• Europe has experienced earlier generic competition in some jurisdictions.
• Emerging markets often provide volume growth but lower net pricing.
• Pediatric products may preserve higher margins because of manufacturing and regulatory complexity.
• Hospital and government tenders can accelerate price reductions after multiple suppliers enter.

The most defensible commercial niches are differentiated suspensions, pediatric dosing, hospital-use presentations and products with manufacturing advantages.

What should a commercial excipient strategy prioritize?

A practical strategy should rank opportunities as follows:

1. Develop a conventional tablet platform for rapid generic entry and broad regulatory coverage.
2. Build a separate 1 mg/mL suspension platform with strong taste masking and dosing-device validation.
3. Evaluate particle-size and surfactant optimization before pursuing complex amorphous systems.
4. Reserve solid-dispersion or lipid technologies for products that demonstrate a clear food-effect or exposure advantage.
5. File patents around composition-process-performance relationships rather than routine excipient selection.
6. Protect manufacturing parameters and analytical methods as trade secrets where patent claims are weak.
7. Generate regional excipient documentation early to support multinational submissions.

Key Takeaways

• Rivaroxaban is a low-solubility small molecule with meaningful excipient sensitivity.
• Conventional tablets remain the largest generic opportunity but face rapid price erosion.
• The best differentiated opportunities are pediatric suspensions, taste-masked products, modified dissolution systems and low-dose manufacturing platforms.
• Rivaroxaban has generic rather than biosimilar competition.
• Xarelto patent and Orange Book analysis must be performed by dosage form, strength, indication and jurisdiction.
• Strong formulation patents should link excipient composition to dissolution, stability, exposure or patient-use performance.
• Pediatric suspension development has higher technical barriers and may support better margins than standard tablets.
• Excipient suppliers can capture value through functional systems, regulatory documentation and formulation know-how, not only commodity ingredients.

FAQs About Rivaroxaban Excipient Strategy

Can rivaroxaban tablets be reformulated without changing the active ingredient?

Yes. A reformulation can change diluents, binders, disintegrants, surfactants, lubricants, coating systems or manufacturing processes, but it must meet applicable quality and bioequivalence requirements.

Which excipient is most important for rivaroxaban dissolution?

No single excipient controls performance in every formulation. Wetting agents, particle-size control, granulation conditions and disintegrant selection typically have the greatest combined impact.

Is a rivaroxaban oral suspension commercially attractive?

Yes. The suspension market has greater development complexity than standard tablets but provides opportunities in pediatric care, feeding-tube administration, taste masking and differentiated dosing.

Can a new rivaroxaban formulation obtain independent patent protection?

Yes, if it demonstrates novelty and nonobviousness. Claims supported by defined composition ranges, solid-state properties, process controls and measurable performance are more defensible than broad claims covering routine excipient combinations.

Does rivaroxaban require a biosimilar development program?

No. Rivaroxaban is a chemically synthesized small molecule. Competitors generally pursue generic-drug approval, including ANDA-based pathways in the United States.

References

1. U.S. Food and Drug Administration. (2024). Xarelto (rivaroxaban) prescribing information. Janssen Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Xarelto for oral suspension prescribing information. Janssen Pharmaceuticals, Inc.

3. U.S. Patent and Trademark Office. (n.d.). Patent term and patent information for U.S. Patent No. 7,157,456. U.S. Department of Commerce.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry.

6. International Council for Harmonisation. (2009). Pharmaceutical development Q8(R2).

7. International Council for Harmonisation. (2023). Assessment and control of DNA reactive impurities in pharmaceuticals to limit potential carcinogenic risk Q3A(R2), Q3B(R2), M7(R2), and related guidance.